Almirall, S.A. (OTC:LBTSF) Q1 2022 Earnings Conference Call May 9 2022 4:00 AM ET Company Participants Carlos Gallardo Piqué - Chairman and President Gianfranco Nazzi - Chief Executive.
- Skin clearance and itch, key signs and symptoms of atopic dermatitis, were significantly improved with lebrikizumab treatment in combination with TCS BARCELONA, Spain, April 11, 2022
More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75 ) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.A. (BME: ALM) announced today at the American Academy of Dermatology (AAD) .
/PRNewswire/ More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity.